The induction of nitric oxide by interleukin-12 and tumor necrosis factor-alpha in human natural killer cells: relationship with the regulation of lytic activity.
We have investigated the interleukin-12 (IL-12) and tumor necrosis factor-alpha (TNFalpha)-induced regulation of human natural killer (NK) cell function and their relationship with nitric oxide (NO) generation. We demonstrate that both cytokines were efficient to trigger the transcription of the inducible nitric oxide synthase (iNOS) mRNA, as detected by reverse transcriptase-polymerase chain reaction (RT-PCR). Western blot analysis and intracytoplasmic fluorescence showed that iNOS protein was also induced by both cytokines. However, our data indicate that NO does not play a significant role in the effector phase of the cytotoxic activity mediated by NK-stimulated cells, inasmuch as the lytic activity was not affected in the presence of specific NO synthase inhibitors. When aminoguanidine (AMG), an inhibitor of iNOS, was added during the afferent phase of NK stimulation with IL-12 and TNFalpha, a subsequent increase in the lytic potential of the effector cells towards the NK-sensitive target cells (K562) and lymphokine-activated killer (LAK) target cells (Daudi) was observed. Conversely, the addition of chemical NO donors during the afferent step resulted in a dose-dependent inhibition of the NK and LAK cytotoxicity. Our data suggest that the enhancement of NK-cell cytotoxic activity resulting from iNOS inhibition may be correlated, at least in part, to an increase in interferon-gamma production and granzyme B expression.
Salvucci
O
O
Laboratoire Cytokines et Immunologie des Tumeurs Humaines, U 487 INSERM, Institut Gustave-Roussy, Villejuif, France; the Interférons et cytokines, Unité 365 INSERM, Institut Curie, Paris, France.
Kolb
J P
JP
Dugas
B
B
Dugas
N
N
Chouaib
S
S
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000906:Antibodies / Q000378:metabolism; D002478:Cells, Cultured; D002956:Citrulline / Q000378:metabolism; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004357:Drug Synergism; D004790:Enzyme Induction / Q000276:immunology; D053804:Granzymes; D006146:Guanidines / Q000494:pharmacology; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D018664:Interleukin-12 / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000201:enzymology / Q000276:immunology / Q000378:metabolism*; D008213:Lymphocyte Activation; D009566:Nitrates / Q000378:metabolism; D009569:Nitric Oxide / Q000096:biosynthesis* / Q000378:metabolism / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000096:biosynthesis / Q000187:drug effects; D052247:Nitric Oxide Synthase Type II; D009573:Nitrites / Q000378:metabolism; D009599:Nitroprusside / Q000494:pharmacology; D012697:Serine Endopeptidases / Q000096:biosynthesis; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D000906:Antibodies; D006146:Guanidines; D009566:Nitrates; D009573:Nitrites; D014409:Tumor Necrosis Factor-alpha; D009599:Nitroprusside; D018664:Interleukin-12; D002956:Citrulline; D009569:Nitric Oxide; D007371:Interferon-gamma; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C509213:GZMB protein, human; D053804:Granzymes; D012697:Serine Endopeptidases; C004479:pimagedine